Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Lab Invest. 2002 Apr;82(4):483-93. doi: 10.1038/labinvest.3780441.
Lab Invest. 2002.
PMID: 11950905
Free article.
Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.
Gorter A, et al. Among authors: blok vt.
Lab Invest. 1996 Jun;74(6):1039-49.
Lab Invest. 1996.
PMID: 8667608
Item in Clipboard
A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ, Gorter A.
Blok VT, et al.
J Immunol. 1998 Apr 1;160(7):3437-43.
J Immunol. 1998.
PMID: 9531304
Item in Clipboard
A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage.
Blok VT, Daha MR, Tijsma OM, Weissglas MG, van den Broek LJ, Gorter A.
Blok VT, et al.
Lab Invest. 2000 Mar;80(3):335-44. doi: 10.1038/labinvest.3780038.
Lab Invest. 2000.
PMID: 10744069
Free article.
Item in Clipboard
Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT, Gelderman KA, Tijsma OH, Daha MR, Gorter A.
Blok VT, et al.
Scand J Immunol. 2003 Jun;57(6):591-9. doi: 10.1046/j.1365-3083.2003.01265.x.
Scand J Immunol. 2003.
PMID: 12791098
Free article.
Item in Clipboard
Cite
Cite